Efficacy and Safety of a DOAC Compared to Unfractionated Heparin and A Low Molecular Weight Heparin in the Prevention of Thromboembolism in Hematopoietic Stem Cell Transplant Recipients.
Saeed AzimiAbbas HajifathaliSayeh ParkhidehJamshid SalamzadehBardia Rahmati-KamelFarzaneh DastanMahshid MehdizadehMahdiye AbiyarghamsariMaria Tavakoli ArdakaniPublished in: Iranian journal of pharmaceutical research : IJPR (2024)
Apixaban, dalteparin, and heparin demonstrated similar effectiveness in preventing thromboembolism in HSCT recipients. Furthermore, the comparison of bleeding rates across the study groups did not reveal significant differences. Larger studies with higher event rates may yield more precise conclusions.